Bloodletting In Multiple Sclerosis

ironjustice

2013-10-28 01:52:53 UTC

On Saturday, October 26, 2013 1:12:47 PM UTC-7, ironjustice wrote:
Iron depletion induced by bloodletting and followed by rhEPO administration as a therapeutic strategy in progressive multiple sclerosis<<

http://www.google.com/patents/WO2010092419A1

Combined treatment of multiple sclerosis
WO 2010092419

A1Abstract
The invention concerns a novel treatment multiple sclerosis, based on induced anaemia, followed by administration of an erythropoiesis-stimulating agent (ESA).
In a preferred embodiment, the ESA is darbopoietin alpha, CERA or Hematide.
The anaemia is induced by successive bloodlettings or by administration of an iron chelator, such as deferiprone, deferoxamine, polyanionic amines, substitued polyaza compounds, desferrithiocon, hydroxybenzyl-ethylenediamine-diacetic acid and pyridoxal isonicotinoyl hydrazone

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh

Man Is A Herbivore!
http://tinyurl.com/4rq595

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk

: A pilot, open-label study with neurophysiological measurements Neurophysiologie Clinique/Clinical Neurophysiology Available online 26 October 2013 A. Créangea, b, 1, , , J.-P. Lefaucheura, c, 1, M.-O. Balleyguierd, F. Galactérosea EA 4391, université Paris-Est, Créteil, France b Service de neurologie, groupe hospitalier Henri-Mondor, AP–HP, Créteil, France c Service de physiologie explorations fonctionnelles, groupe hospitalier Henri–Mondor, AP-HP, Créteil, France d Laboratoire de biochimie et génétique, groupe hospitalier Henri-Mondor, AP–HP, Créteil, France e Unité des maladies génétiques du globule rouge, Groupe Hospitalier Henri Mondor, AP-HP, Université Paris Est, Créteil, France Summary Objectives To evaluate the concept that iron depletion (ID) induced by bloodletting and followed by recombinant human erythropoietin (rhEPO) administration could be a therapeutic strategy in progressive multiple sclerosis (PMS) and that it could be assessed by neurophysiological measurements. Patients and methods In four patients with PMS, bloodletting was performed until ID was induced, and then rhEPO was administered (300 UI/kg/week). The changes induced by the treatment were assessed by clinical scores, biological tests, and neurophysiological study of cortical excitability using transcranial magnetic stimulation techniques. Results The treatment was well tolerated except for muscle cramps and one popliteal vein thrombosis in a patient confined to chair. ID was obtained within 28 weeks and was associated with endogenous production of EPO. No bloodletting was further required during a six-month period after introduction of rhEPO. At the end of the follow-up (up to one year), fatigue and walking capacities tended to improve in two patients. Neurophysiological changes were characterized by an increased cortical excitability, including a decrease of motor thresholds and an enhancement of intracortical facilitation and cerebellothalamocortical inhibition. Conclusions The combined ID-rhEPO therapy could authorize a prolonged administration of rhEPO in PMS patients, able to modify cortical excitability of the glutamatergic and gabaergic circuits. These preliminary data are encouraging to design a larger, controlled therapeutical trial to assess the value of such a strategy to improve functional symptoms in PMS patients, and maybe to prevent axonal degeneration. Neurophysiological measurements based on cortical excitability studies could provide sensitive parameters to evaluate treatment-induced changes in this context. Who loves ya. Tom Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh Man Is A Herbivore! http://tinyurl.com/4rq595 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk